LGMD2I clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
open to eligible people ages 18-65
The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
at UC Irvine
Our lead scientists for LGMD2I research studies include Tahseen Mozaffar, MD.
Last updated: